Mehrdad Payandeh
Kermanshah University of Medical Sciences, Kermanshah, Iran
Title: Treatment and survival in patients with chronic myeloid leukemia in chronic phase (CML-CP) in West Iran
Biography
Biography: Mehrdad Payandeh
Abstract
CML includes 30% of all leukemias, and occurs from childhood to old age. The present study was a retrospective analysis of chronic phase CML patients registered to Hematology Clinic in Kermanshah, Iran, with checking of treatment options in this disease. Between of 2002 to 2014, 85 CML patients referred to Hematology Clinic that selected them for our study. We surveyed age, sex, B-symptoms, Splenomegaly, sokal score, hasford score, treatment and survival in all patients. Philadelphia chromosome analysis was done for each patient by conventional cytogenetics. We compared treatment in the patients with three drugs (Imatinib, hydroxyurea (HU) and Interferon alpha (IFN-α)). The mean age of the patients at diagnosis was 47.5±14.5 years (range, 23-82 years), with 43 patients (50.6%) male. 13 patients (15.3%) referred to clinic for the first time with B-symptoms and 44 patients (51.8%) had splenomegaly. Sokal Score for 77 patients (90.6%) was low, 4(4.7%) was intermediate and 4(4.7%) was high, but Hasford (Euro) Score for all patients was low. The 5-year survival rate for treated patients with Imatinib, Imatinib plus HU and Imatinib plus HU plus IFN-α was 90.5%, 81.1% and 55.6%, respectively. The mean age and median age at diagnosis for the patients are around 40-50 years. Also, the results show that Imatinib therapy alone approves survival in CML patients compared to HU or IFN-α. Combination of IFN-α and/or HU with Imatinib probably reduce survival.
